CRISPR Therapeutics gains FDA approval for CASGEVY, moving into commercial biotech stage.

CRISPR Therapeutics has advanced from a speculative biotech firm to a commercial-stage company with the FDA approval of its gene-editing therapy CASGEVY. This approval validates its CRISPR/Cas9 platform and supports its pipeline targeting large markets in cardiovascular, autoimmune, oncology, and diabetes diseases. Despite a strong cash position and valuable partnerships, most of its pipeline remains early stage, posing execution risks. The company is viewed as a speculative investment, with more attractive valuation potential below $52 per share.